ATE461217T1 - Glp-1-verbindungen - Google Patents

Glp-1-verbindungen

Info

Publication number: ATE461217T1
Authority: AT; Austria
Prior art keywords: compounds; glp; therapeutic use; novel glp; novel
Prior art date: 2003-12-18

Application number

AT04803037T

Other languages

English (en)

Inventor

Nils Langeland Johansen

Jesper Lau

Kjeld Madsen

Thomas Kruse Hansen

Jeppe Sturis

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-18

Filing date

2004-12-17

Publication date

2010-04-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34702152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE461217(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-12-17 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2010-04-15 Application granted granted Critical

2010-04-15 Publication of ATE461217T1 publication Critical patent/ATE461217T1/de

Links

DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 2
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Zoology (AREA)
Hematology (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Nutrition Science (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT04803037T 2003-12-18 2004-12-17 Glp-1-verbindungen ATE461217T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DKPA200301885		2003-12-18
DKPA200401090		2004-07-09
PCT/DK2004/000886 WO2005058954A1 (en)	2003-12-18	2004-12-17	Novel glp-1 compounds

Publications (1)

Publication Number	Publication Date
ATE461217T1 true ATE461217T1 (de)	2010-04-15

Family

ID=34702152

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04803037T ATE461217T1 (de)	2003-12-18	2004-12-17	Glp-1-verbindungen

Country Status (12)

Country	Link
US (2)	US20070042956A1 (de)
EP (1)	EP1704165B1 (de)
JP (1)	JP2007537141A (de)
KR (1)	KR20060135661A (de)
AT (1)	ATE461217T1 (de)
AU (1)	AU2004298424A1 (de)
BR (1)	BRPI0417717A (de)
CA (1)	CA2549582A1 (de)
DE (1)	DE602004026113D1 (de)
MX (1)	MXPA06006745A (de)
RU (1)	RU2006120079A (de)
WO (1)	WO2005058954A1 (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2006520818A (ja)	2003-03-19	2006-09-14	イーライリリーアンドカンパニー	ポリエチレングリコール結合ｇｌｐ−１化合物
ATE461217T1 (de)	2003-12-18	2010-04-15	Novo Nordisk As	Glp-1-verbindungen
TWI376234B (en)	2005-02-01	2012-11-11	Msd Oss Bv	Conjugates of a polypeptide and an oligosaccharide
CA2601745A1 (en) *	2005-02-16	2006-08-24	Novo Nordisk A/S	Insulinotropic agents conjugated with structurally well defined branched polymers
US8603972B2 (en)	2005-03-18	2013-12-10	Novo Nordisk A/S	Extended GLP-1 compounds
TWI362392B (en)	2005-03-18	2012-04-21	Novo Nordisk As	Acylated glp-1 compounds
WO2007047834A2 (en) *	2005-10-18	2007-04-26	Biocon Limited	Oral peptide conjugates for metabolic diseases
CN101296708B (zh)	2005-10-26	2011-12-07	伊莱利利公司	选择性vpac2受体肽激动剂
CA2913805A1 (en)	2005-11-07	2007-05-18	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting physiological solubility and stability
EP2364735A3 (de)	2005-12-16	2012-04-11	Nektar Therapeutics	Verzweigte PEG-Kon jugate von GLP-1
JP2009534423A (ja) *	2006-04-20	2009-09-24	アムジェンインコーポレイテッド	Ｇｌｐ−１化合物
FR2904627B1 (fr) *	2006-08-04	2008-11-07	Pasteur Institut	Nouveaux peptides actives, purifies et isoles, derives du recepteur cd4 (mini-cd4) et leur procece de preparation
CN101125207B (zh) *	2006-11-14	2012-09-05	上海华谊生物技术有限公司	带有聚乙二醇基团的艾塞丁或其类似物及其制剂和用途
RU2477286C2 (ru) *	2007-01-05	2013-03-10	Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн	АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
CA2677932A1 (en)	2007-02-15	2008-08-21	Indiana University Research And Technology Corporation	Glucagon/glp-1 receptor co-agonists
WO2009030771A1 (en)	2007-09-05	2009-03-12	Novo Nordisk A/S	Peptides derivatized with a-b-c-d- and their therapeutical use
EP2190872B1 (de)	2007-09-05	2018-03-14	Novo Nordisk A/S	Glucagon-like peptid-1-derivate und ihre pharmazeutische verwendung
US20100292133A1 (en)	2007-09-05	2010-11-18	Novo Nordisk A/S	Truncated glp-1 derivaties and their therapeutical use
GB0717399D0 (en) *	2007-09-07	2007-10-17	Uutech Ltd	Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission
EP2200626A4 (de) *	2007-09-07	2012-02-15	Ipsen Pharma Sas	Analoga von exendin-4 und exendin-3
ES2509883T3 (es) *	2007-10-30	2014-10-20	Indiana University Research And Technology Corporation	Antagonistas de glucagón
MX2010004298A (es) *	2007-10-30	2010-05-03	Univ Indiana Res & Tech Corp	Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1.
EP2249853A4 (de) *	2008-01-30	2012-12-26	Univ Indiana Res & Tech Corp	Peptid-prodrugs auf esterbasis
EP2087911A1 (de) *	2008-02-06	2009-08-12	Institut Pasteur	Konjugierte Moleküle mit einem Peptid aus dem mit einem Polyanion gekoppelten CD4-Rezeptor zur Behandlung von AIDS
WO2009152289A1 (en) *	2008-06-11	2009-12-17	Indiana University Research And Technology Corporation	Methods for enhancing adsorption of molecules
US8450270B2 (en) *	2008-06-17	2013-05-28	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
AR072160A1 (es)	2008-06-17	2010-08-11	Univ Indiana Res & Tech Corp	Co-agonistas del receptor de glucagon/glp-1
CN102105159B (zh) *	2008-06-17	2015-07-08	印第安纳大学研究及科技有限公司	基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
MX2011000847A (es)	2008-08-06	2011-02-25	Novo Nordisk Healthcare Ag	Proteinas conjugadas con eficacia prolongada in vivo.
TW201012829A (en) *	2008-09-22	2010-04-01	Ipsen Mfg Ireland Ltd	Process for the synthesis of (Aib8,35)hGLP-1(7-36)-NH2
PE20120332A1 (es)	2008-12-19	2012-04-14	Univ Indiana Res & Tech Corp	Profarmacos de peptido de la superfamilia de glucagon basado en amida
MX2011007736A (es)	2009-01-22	2011-09-06	Novo Nordisk Healthcare Ag	Compuestos de hormona del crecimiento estables.
EP2443146B1 (de)	2009-06-16	2016-10-05	Indiana University Research And Technology Corporation	Gip-rezeptor-aktive glucagon-verbindungen
WO2011015649A1 (en)	2009-08-06	2011-02-10	Novo Nordisk Health Care Ag	Growth hormones with prolonged in-vivo efficacy
JP6006118B2 (ja)	2009-12-16	2016-10-12	ノヴォノルディスクアー／エス	Ｇｌｐ−１アナログ及び誘導体
US8703701B2 (en)	2009-12-18	2014-04-22	Indiana University Research And Technology Corporation	Glucagon/GLP-1 receptor co-agonists
MX338357B (es)	2010-01-22	2016-04-13	Novo Nordisk Healthcare Ag	Compuestos estables de la hormona de crecimiento.
RS59459B1 (sr)	2010-01-22	2019-11-29	Novo Nordisk Healthcare Ag	Hormoni rasta sa produženom in-vivo efikasnošću
KR20120123443A (ko)	2010-01-27	2012-11-08	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
JP6050746B2 (ja)	2010-05-13	2016-12-21	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションIndiana University Research And Technology Corporation	Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
MX2012013001A (es)	2010-05-13	2013-02-26	Univ Indiana Res & Tech Corp	Peptidos de la superfamilia de glucagon que presentan actividad del receptor nuclear de hormonas.
EP2588126A4 (de)	2010-06-24	2015-07-08	Univ Indiana Res & Tech Corp	Amidbasierte glucagon-superfamilien-peptid-prodrugs
SI2651398T1 (en)	2010-12-16	2018-04-30	Novo Nordisk A/S	SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
US8507428B2 (en)	2010-12-22	2013-08-13	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting GIP receptor activity
PL2696687T3 (pl)	2011-04-12	2017-06-30	Novo Nordisk A/S	Pochodne podwójnie acylowanej GLP-1
KR20140043793A (ko)	2011-06-22	2014-04-10	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	글루카곤/glp-1 수용체 공동-작용물질
RS56173B1 (sr)	2011-06-22	2017-11-30	Univ Indiana Res & Tech Corp	Koagonisti receptora za glukagon/glp-1 receptora
JP6324315B2 (ja)	2011-11-17	2018-05-16	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	グルココルチコイド受容体の活性を示すグルカゴンスーパーファミリーのペプチド
HRP20181447T1 (hr)	2012-03-22	2018-11-02	Novo Nordisk A/S	Pripravci glp-1 peptida i njihova priprava
ES2965469T3 (es)	2012-03-22	2024-04-15	Novo Nordisk As	Composiciones que comprenden un agente de suministro y preparación de estas
PT2827845T (pt)	2012-03-22	2019-03-29	Novo Nordisk As	Composições compreendendo um agente de entrega e sua preparação
EP2846823B1 (de)	2012-05-08	2019-12-04	Novo Nordisk A/S	Zweifach acylierte glp-1-derivate
CN104411322B (zh) *	2012-05-08	2017-05-24	诺和诺德股份有限公司	双酰化glp‑1衍生物
JP6517690B2 (ja)	2012-06-20	2019-05-22	ノヴォノルディスクアー／エス	ペプチド及び送達剤を含む錠剤製剤
CN104583232B (zh)	2012-06-21	2018-04-13	印第安纳大学研究及科技有限公司	展现gip受体活性的胰高血糖素类似物
WO2014060472A1 (en)	2012-10-17	2014-04-24	Novo Nordisk A/S	Fatty acid acylated amino acids for oral peptide delivery
JP6538645B2 (ja)	2013-03-14	2019-07-03	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	インスリン‐インクレチン複合物
US11045523B2 (en)	2013-04-05	2021-06-29	Novo Nordisk Healthcare Ag	Formulation of growth hormone albumin-binder conjugate
KR102272671B1 (ko)	2013-05-02	2021-07-06	노보 노르디스크 에이/에스	Glp-1 화합물의 경구 투여
US10626156B2 (en)	2013-12-06	2020-04-21	Jie Han	Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
CN108271356A (zh)	2014-09-24	2018-07-10	印第安纳大学研究及科技有限公司	肠降血糖素-胰岛素缀合物
ES2630106T3 (es)	2014-10-07	2017-08-18	Cyprumed Gmbh	Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
JP2018529749A (ja)	2015-10-07	2018-10-11	シプルメット・ゲーエムベーハー	ペプチド薬物を経口送達するための医薬製剤
WO2018065634A1 (en)	2016-10-07	2018-04-12	Cyprumed Gmbh	Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
KR102665710B1 (ko)	2017-08-24	2024-05-14	노보 노르디스크 에이/에스	Glp-1 조성물 및 그 용도
JP6898518B2 (ja)	2018-02-02	2021-07-07	ノヴォノルディスクアー／エス	Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
WO2019193204A1 (en)	2018-04-06	2019-10-10	Cyprumed Gmbh	Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
TWI829687B (zh)	2018-05-07	2024-01-21	丹麥商諾佛儂迪克股份有限公司	包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
WO2020127476A1 (en)	2018-12-19	2020-06-25	Krka, D.D., Novo Mesto	Pharmaceutical composition comprising glp-1 analogue
WO2021123228A1 (en)	2019-12-18	2021-06-24	Krka, D.D., Novo Mesto	Pharmaceutical composition comprising glp-1 analogue
HRP20241159T1 (hr)	2020-02-07	2024-12-06	Gasherbrum Bio, Inc.	Heterociklički agonisti za glp-1
CN111253475B (zh) *	2020-02-18	2021-03-09	江苏诺泰澳赛诺生物制药股份有限公司	Glp-1激动多肽化合物及其盐与合成方法及用途
CN115461044B (zh)	2020-04-29	2025-06-10	诺和诺德股份有限公司	包含glp-1激动剂和组氨酸的固体组合物
TW202206429A (zh)	2020-04-29	2022-02-16	美商迦舒布魯姆生物有限公司	雜環ｇｌｐ—１促效劑
JP2023537501A (ja)	2020-08-06	2023-09-01	ガシャーブラム・バイオ・インコーポレイテッド	ヘテロ環ｇｌｐ－１アゴニスト
EP4210680A1 (de)	2020-09-07	2023-07-19	Cyprumed GmbH	Verbesserte pharmazeutische formulierungen von glp-1-rezeptoragonisten
CN114729060B (zh)	2020-09-30	2022-11-25	北京质肽生物医药科技有限公司	多肽缀合物和使用方法
WO2023012263A1 (en)	2021-08-04	2023-02-09	Novo Nordisk A/S	Solid oral peptide formulations
JP2025509281A (ja)	2022-03-09	2025-04-11	ガシャーブラム・バイオ・インコーポレイテッド	ヘテロ環式ｇｌｐ－１アゴニスト
US20250206757A1 (en)	2022-03-21	2025-06-26	Gasherbrum Bio, Inc.	5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
EP4323413A4 (de)	2022-03-30	2025-10-15	Beijing Ql Biopharmaceutical Co Ltd	Flüssige pharmazeutische zusammensetzungen aus polypeptidkonjugaten und verfahren zur verwendung davon
US20250250269A1 (en)	2022-04-14	2025-08-07	Gasherbrum Bio, Inc.	Heterocyclic glp-1 agonists
JP2026502943A (ja)	2022-12-30	2026-01-27	アルギファルマエーエス	経口投与されるポリペプチド治療剤の全身バイオアベイラビリティを高める組成物および方法
WO2024165571A2 (en)	2023-02-06	2024-08-15	E-Therapeutics Plc	Inhibitors of expression and/or function
WO2025125576A2 (en)	2023-12-15	2025-06-19	E-Therapeutics Plc	Inhibitors of expression and/or function
EP4686757A1 (de)	2024-07-31	2026-02-04	e-therapeutics PLC	Inhibitoren der expression und/oder funktion
WO2025133348A1 (en)	2023-12-22	2025-06-26	E-Therapeutics Plc	Inhibitors of expression and/or function
WO2025196502A1 (en)	2024-03-20	2025-09-25	North Carolina Agricultural & Technical State University	Choline kinase inhibitors as a therapeutic treatment for obesity

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3862167A (en)	1965-08-11	1975-01-21	Mitsui Toatsu Chemicals	Certain 2-acylamine-4-methyl-5-halothiazoles
US5545618A (en) *	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
ATE164852T1 (de)	1990-01-24	1998-04-15	Douglas I Buckley	Glp-1-analoga verwendbar in der diabetesbehandlung
US5932462A (en)	1995-01-10	1999-08-03	Shearwater Polymers, Inc.	Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en)	1995-07-07	1997-09-30	Shearwater Polymers, Inc.	Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
IL128332A0 (en)	1996-08-30	2000-01-31	Novo Nordisk As	GLP-1 derivatives
WO1999043706A1 (en)	1998-02-27	1999-09-02	Novo Nordisk A/S	Derivatives of glp-1 analogs
BR9913284A (pt)	1998-08-28	2001-05-15	Lilly Co Eli	Métodos para administrar peptìdeos insulinotrópicos
MY155270A (en)	1998-09-24	2015-09-30	Lilly Co Eli	Use of glp-1 or analogs in treatment of stroke
CZ295044B6 (cs) *	1998-12-07	2005-05-18	Societe De Conseils De Recherches Et D'application	Analogy GLP-1, mající kyselinu aminoizomáselnou na pozicích 8 a 35, jejich použití a farmaceutické prostředky je obsahující
CA2372214A1 (en) *	1999-04-30	2000-11-09	Amylin Pharmaceuticals, Inc.	Modified exendins and exendin agonists
US6924264B1 (en) *	1999-04-30	2005-08-02	Amylin Pharmaceuticals, Inc.	Modified exendins and exendin agonists
EP1076066A1 (de)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptide zur Senkung des Blutglukosespiegels
KR100345214B1 (ko) *	1999-08-17	2002-07-25	이강춘	생체적합성 고분자가 수식된 펩타이드의 비점막 전달
WO2001051071A2 (en)	2000-01-11	2001-07-19	Novo Nordisk A/S	Transepithelial delivery of glp-1 derivatives
US6858580B2 (en)	2001-06-04	2005-02-22	Nobex Corporation	Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6864069B2 (en) *	2001-10-05	2005-03-08	Bayer Pharmaceuticals Corporation	Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
AR036711A1 (es) *	2001-10-05	2004-09-29	Bayer Corp	Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
US20030191056A1 (en) *	2002-04-04	2003-10-09	Kenneth Walker	Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
JP2006501820A (ja) *	2002-09-06	2006-01-19	バイエル・フアーマシユーチカルズ・コーポレーシヨン	修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法
JP2006520818A (ja) *	2003-03-19	2006-09-14	イーライリリーアンドカンパニー	ポリエチレングリコール結合ｇｌｐ−１化合物
DK2275439T3 (da)	2003-08-05	2014-05-12	Novo Nordisk As	Hidtil ukendte insulinderivater
WO2005028499A2 (en) *	2003-09-19	2005-03-31	The Scripps Research Institute	Peptide that binds to a broadly neutralizing anti-hiv antibody-structure of 4e10 fab fragment complex, uses thereof, compositions therefrom
ATE461217T1 (de)	2003-12-18	2010-04-15	Novo Nordisk As	Glp-1-verbindungen
CN101227942B (zh)	2005-07-27	2010-10-20	诺沃-诺迪斯克有限公司	具有剂量限制机构和另外的安全机构的注射器设备
CN101925374B (zh)	2008-01-23	2014-11-26	诺沃-诺迪斯克有限公司	用于注射所分配剂量的液体药物的设备

2004
- 2004-12-17 AT AT04803037T patent/ATE461217T1/de not_active IP Right Cessation
- 2004-12-17 WO PCT/DK2004/000886 patent/WO2005058954A1/en not_active Ceased
- 2004-12-17 DE DE602004026113T patent/DE602004026113D1/de not_active Expired - Lifetime
- 2004-12-17 JP JP2006544220A patent/JP2007537141A/ja not_active Withdrawn
- 2004-12-17 EP EP04803037A patent/EP1704165B1/de not_active Revoked
- 2004-12-17 CA CA002549582A patent/CA2549582A1/en not_active Abandoned
- 2004-12-17 BR BRPI0417717-7A patent/BRPI0417717A/pt not_active IP Right Cessation
- 2004-12-17 KR KR1020067011699A patent/KR20060135661A/ko not_active Withdrawn
- 2004-12-17 AU AU2004298424A patent/AU2004298424A1/en not_active Abandoned
- 2004-12-17 MX MXPA06006745A patent/MXPA06006745A/es not_active Application Discontinuation
- 2004-12-17 RU RU2006120079/13A patent/RU2006120079A/ru unknown
2006
- 2006-06-16 US US11/454,804 patent/US20070042956A1/en not_active Abandoned
2012
- 2012-05-16 US US13/473,154 patent/US9920106B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20120289453A1 (en)	2012-11-15
MXPA06006745A (es)	2006-08-18
US9920106B2 (en)	2018-03-20
US20070042956A1 (en)	2007-02-22
EP1704165B1 (de)	2010-03-17
AU2004298424A1 (en)	2005-06-30
KR20060135661A (ko)	2006-12-29
EP1704165A1 (de)	2006-09-27
BRPI0417717A (pt)	2007-04-03
JP2007537141A (ja)	2007-12-20
RU2006120079A (ru)	2008-01-27
DE602004026113D1 (de)	2010-04-29
WO2005058954A1 (en)	2005-06-30
CA2549582A1 (en)	2005-06-30

Legal Events

Date	Code	Title	Description
2010-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE461217T1 (de)	2010-04-15	Glp-1-verbindungen
NO20075342L (no)	2007-12-18	Acylerte GLP-1-forbindelser.
NO20044597L (no)	2004-10-27	Kjemiske forbindelser
NO20052914D0 (no)	2005-06-15	Terapeutiske forbindelser
NO20053974D0 (no)	2005-08-25	Tienopyrimidinforbindelser og anvendelse derav.
EP1495141A4 (de)	2006-03-22	Hiv-therapeutikum
SE0301653D0 (sv)	2003-06-05	Novel compounds
DK1572229T3 (da)	2014-06-23	Stabilt terapeutisk fibrinogen
EP1570270A4 (de)	2010-09-22	Therapeutische biokonjugate
SE0301650D0 (sv)	2003-06-04	Novel compounds
DK1597171T3 (da)	2013-02-11	Terapeutisk mikroskum
NL1024677A1 (nl)	2004-05-06	Therapeutische prolinederivaten.
DK1553950T3 (da)	2007-10-15	Terapeutisk behandling
NO20050689L (no)	2005-03-21	Terapeutisk anvendelse
ATE399532T1 (de)	2008-07-15	Medizinische seife
NO20053189D0 (no)	2005-06-29	HVC-kombinasjonsterapi.
IS7441A (is)	2004-09-08	Peptíðdeformýlasatálmar
NO20022747D0 (no)	2002-06-07	Behandlingsstol
FI20021817A0 (fi)	2002-10-14	Kanyyli
DE60232650D1 (de)	2009-07-30	Peptiddeformylaseinhibitoren
SE0200450D0 (sv)	2002-02-13	Therapeutic agents
SE0203826D0 (sv)	2002-12-20	Therapeutic agents
SE0201783D0 (sv)	2002-06-11	Medical use
SE0200410D0 (sv)	2002-02-05	Novel use
SE0202239D0 (sv)	2002-07-17	Novel use